Itraderm DS Capsule contains Itraconazole 200 mg, a potent antifungal agent belonging to the triazole class. It is primarily indicated for the treatment of various systemic and superficial fungal infections caused by susceptible dermatophytes, yeasts, and molds. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itraderm DS Capsule is commonly prescribed for conditions such as onychomycosis, tinea corporis, tinea cruris, tinea pedis, and candidiasis. The medication is administered orally, with dosage and duration tailored according to the severity and type of infection. It is important to take Itraderm DS Capsule with food to enhance absorption. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully evaluated due to itraconazole’s effect on cytochrome P450 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Itraderm DS Capsule should be used under strict medical supervision to ensure safety and efficacy.